Prostate Cancer Studies Currently Recruiting Participants at the University of Chicago Comprehensive Cancer Center

Study Number Title
12803B Quality of Life after Radical Prostatectomy
12278A Clinical Urology Research Screening Protocol
Select
15244B IRB 15244B: CALGB 90203: Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer
14934A Radiotherapy for Prostate Cancer: Dosimetric and Clinical Outcomes in the IMRT Era
10-174-B Feasibility of Collection & Analysis of Circulating and Disseminated Tumor Cells from men with Advanced Prostate Cancer
Select
10-487-A The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing
Select
10-662-B A phase I, open-label study of the safety and pharmacokinetics of escalating doses of DSTP3086S in patients with metastatic castration-resistant prostate cancer
Select
10-625-A A feasibility study of oral hormonal therapy and radiation for non-metastatic, intermediate or high risk prostate cancer in men 70 and older or with medical comorbidities
Select
11-0110 CALGB 70807: The Men¿s Eating and Living (MEAL) Study: A Randomized Trial of Diet to Alter Disease Progression in Prostate Cancer Patients on Active Surveillance
11-0061 Evaluation of endorectal MRI for risk stratification, treatment planning, and workup after biochemical failure in patients with adenocarcinoma of the prostate
Select
11-0621 A Phase I/II Study of Docetaxel, Prednisone and Pazopanib in Men with Metastatic Castrate-resistant cancer and poor-risk features.
Select
12-0114 The CATCH Prostate Cancer Trial: Cabazitaxel and Tasquinimod in Men With Castration-Resistant Heavily Pre-treated Prostate Cancer
IRB13-0756 Quantitative DCEMRI of Prostate Cancer ¿ Correlation with Gold Standards
IRB14-0081 Phase I, Multicenter, Cohort Dose Escalation Trial to Determine the Safety, Tolerance, and Maximum Tolerated Dose of DCR-MYC, a Lipid Nanoparticle (LNP)-Formulated Small Inhibitory RNA (siRNA) Oligonucleotide Targeting MYC, in Patients with Refractory Locally Advanced or Metastatic Solid Tumor Malignancies, Multiple Myeloma, or Lymphoma
Select
IRB14-0105 A Phase 1, Open-Label, Dose Escalation Study of MGA271 (Fc-optimized Humanized Anti-B7-H3 Monoclonal Antibody) in Patients with Refractory B7-H3-Expressing Neoplasms or Neoplasms Whose Vasculature Expresses B7-H3

To learn more about cancer clinical trials or to make an appointment, call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials). Although our objective is to provide an updated listing of clinical trials, please note that a listing here does not guarantee that a trial is open or available to any specific patient. Additional trials may be available that are not listed. Complete information is available only from a treating physician.